MyVisionTest News Archive

Displaying news items tagged with macular edema (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7   >> Last

Diabetes
Mar 27, 2011
The National electronic Library for Medicines in the European Union (EU) has published a review that summarizes the clinical trial data investigating the safety and effectiveness of Lucentis, Macugen, and Iluvien in the treatment of diabetic macular edema. Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy and can...

Full Article


Diabetes
Mar 8, 2011
Genentech announced today that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness....

Full Article


Diabetic retinopathy
Jan 21, 2011
The European Commission has granted Novartis a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME), a leading cause of blindness in the working-age population in most developed countries. Laser therapy, the current standard of care, has provided stabilization of vision in many...

Full Article


Central retinal vein occlusion
Oct 16, 2010
Monthly Lucentis (ranibizumab) significantly increased best-corrected visual acuity (BCVA) and decreased macular edema, compared with sham, in patients with central retinal vein occlusion (CRVO), according to a new study. Until recently, there has been no effective therapy for macular edema secondary to central retinal vein occlusion (CRVO)....

Full Article


Avastin
Oct 16, 2010
A case report describes development of ischemic maculopathy following treatment of diabetic macular edema with Avastin It has been recently documented that Lucentis causes retinal arteriolar vasoconstiction, and this has the potential to induce or worsen retinal ischemia (oxygen deprivation). It has been suggested that anti-VEGF agents be used...

Full Article


Diabetes
Sep 20, 2010
Two-year results from a phase 2 trial suggest that anti-VEGF therapy reduces retinal thickness and significantly improves visual acuity in patients with diabetic retinopathy. Combination therapy with laser may reduce the number of injections required, as well as further reducing foveal thickness, Dean Eliott, MD, said at the American Society of...

Full Article


The Iluvien insert, shown on a human finger to indicate size
Sep 20, 2010
The U.S. Food and Drug Administration has granted priority review status to Alimera Sciences' new drug application for its Iluvien intravitreal insert, the company announced in a press release. With the priority review status, which accelerates the FDA's standard review time from 10 months to 6 months, Alimera could receive a response for the...

Full Article


VEGF-Trap
Sep 20, 2010
The GALILEO study has recently started phase 3 to assess the efficacy and safety of VEGF Trap-Eye in the treatment of macular edema in central retinal vein occlusion, a speaker announced here. "Enrollment of 117 patients from 10 countries was completed in July," Frank Holz, MD, said at the Euretina meeting here preceding the European Society...

Full Article


Central retinal vein occlusion
Sep 20, 2010
Macular edema due to branch retinal vein occlusion or central retinal vein occlusion can be effectively reduced using the Ozurdex dexamethasone intravitreal implant, but early treatment is mandatory, according to data from the multicenter GENEVA study. "Patients who were treated early showed a visual acuity improvement of three or more lines,...

Full Article


Central retinal vein occlusion
Aug 26, 2010
The European Medicines Agency has granted Allergan marketing authorization for its dexamethasone intravitreal implant for treating macular edema secondary to retinal vein occlusion, the company announced in a press release. With the approval, Ozurdex (dexamethasone 0.7 mg intravitreal implant) becomes the first and only therapeutic agent...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7   >> Last
Most Popular
Less - past - More